

SCHERING PLOUGH CORP

Form 8-K/A

January 22, 2008

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 19, 2007
SCHERING PLOUGH CORPORATION
(Exact Name of Registrant as Specified in its Charter)**

New Jersey
(State or Other Jurisdiction of
Incorporation)

1-6571
(Commission File Number)

22-1918501
(IRS Employer
Identification Number)

2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of Principal Executive Office)

Registrant's telephone number, including area code: (908) 298-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

SIGNATURES

Exhibit Index

EX-99.2: Unaudited pro forma condensed combined financial statements

Table of Contents

Explanatory Note

On November 26, 2007, Schering-Plough Corporation (Schering-Plough) filed a Form 8-K to report that on November 19, 2007, Schering-Plough closed the acquisition of Organon BioSciences N.V. from Akzo Nobel N.V. Schering-Plough is filing this amendment to Form 8-K to include pro forma financial information that was permitted to be excluded from the November 26, 2007 Form 8-K. The combined financial statements of the OBS Group were included in Schering-Plough Corporation's registration statement on Form S-3, filed on August 2, 2007, and are therefore not required to be filed as part of this Report.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(b) Pro forma financial information

The following Schering-Plough Corporation unaudited pro forma condensed combined financial statements are attached hereto as Exhibit 99.2 and are incorporated herein by reference:

Unaudited pro forma condensed combined balance sheet as of September 30, 2007

Unaudited pro forma condensed statement of combined operations for the nine months ended September 30, 2007

Unaudited pro forma condensed statement of combined operations for the year ended December 31, 2006

Notes to unaudited pro forma condensed combined financial statements

(d) Exhibits

99.1 * Press release dated November 19, 2007 titled Schering-Plough Completes Acquisition of Organon BioSciences

99.2 Unaudited pro forma condensed combined financial statements

* Previously filed
as an exhibit to
the Company's
Current Report
on Form 8-K,
filed on
November 26,
2007

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation

By: /s/ Steven H. Koehler

Steven H. Koehler

Vice President and Controller

Date: January 22, 2008

Table of Contents

Exhibit Index

Exhibit

Number Description

99.1 * Press release dated November 19, 2007 titled Schering-Plough Completes Acquisition of Organon BioSciences

99.2 Unaudited pro forma condensed combined financial statements

* Previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on November 26, 2007